# US 2026/0061027 A1 · Nasal delivery of apigenin and cyclic peptide inhibitors of mitochondrial fission

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0061027 A1
- Document ID: US20260061027A1
- Status: Published application
- Kind: A1
- Application number: 18/941,875
- Filed: 2024-11-08
- Published: 2026-03-05
- Earliest claimed: 2024-08-30
- Assignees: NeuroTher, LLC
- Applicants: NeuroTher, LLC
- Inventors: Bhanu Pratap Jena; Won Jin Cho; Xin Qi; Guillermo G. Marmol
- Web page: https://patentgrep.com/patent/US20260061027A1

## CPC

- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 9/0043: {Nose}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are compositions and/or methods of use of the compositions for patients with neuronal diseases such as AD, Parkinson's, Huntington's, multiple sclerosis, and ALS. In certain embodiments flavonoids alone, or in a pharmaceutical preparation, are administered through the nasal olfactory route. In certain embodiments the flavonoid is apigenin and the neural disease is Alzheimer's. Targeted dosages may affect mitochondrial function in brain neural cells thus ameliorating a neural disease. In some embodiments a porosome complex is administered for reconstitution into a neural cell. In certain embodiments, one or more macrocyclic or linear peptides are administered.

## Claims

### Claim 1

A composition comprising:
a pharmaceutically acceptable preparation of a flavonoid and at least one macrocyclic peptide associated with mitochondrial fission.

### Claim 2 (depends on 1)

The composition of claim 1 wherein the composition is a nanoemulsion for nasal administration.

### Claim 3 (depends on 1)

The composition of claim 1 wherein the at least one peptide encodes a Drp1 adaptor protein or part thereof.

### Claim 4 (depends on 1)

The composition of claim 1 wherein the macrocyclic peptide is based on DA1.

### Claim 5 (depends on 4)

The composition of claim 4 wherein the macrocyclic peptide is DA44 or DA45.

### Claim 6 (depends on 4)

The composition of claim 4 further comprising one or more additional peptides.

### Claim 7 (depends on 6)

The composition of claim 6 wherein the one or more additional peptides are selected from the group of: DA44, DA45, linear DA1, and combinations thereof.

### Claim 8 (depends on 1)

The composition of claim 1 wherein the flavonoid is apigenin.

### Claim 9

A composition, comprising:
apigenin; and,
at least one DA1 based macrocyclic peptide.

### Claim 10 (depends on 9)

The composition of claim 9 wherein the at least one macrocyclic peptide is DA44 or DA45.

### Claim 11 (depends on 9)

The composition of claim 9 wherein the composition further comprises at least one additional pharmaceutical excipient.

### Claim 12 (depends on 11)

The composition of claim 11 wherein the composition is prepared in the form of a nanoemulsion.

### Claim 13 (depends on 11)

The composition of claim 11 wherein the composition is prepared in the form of a suspended mist, powder, or solution.

### Claim 14 (depends on 1)

A method, comprising:
administering to a subject the composition of claim 1.
